Display options
Cite
Zhao B, Dierichs L, Gu JN, et al. TFEB-mediated lysosomal biogenesis and lysosomal drug sequestration confer resistance to MEK inhibition in pancreatic cancer. Cell Death Discov. 2020;6:12doi: 10.1038/s41420-020-0246-7.
Zhao, B., Dierichs, L., Gu, J. N., Trajkovic-Arsic, M., Axel Hilger, R., Savvatakis, K., Vega-Rubin-de-Celis, S., Liffers, S. T., Peña-Llopis, S., Behrens, D., Hahn, S., Siveke, J. T., & Lueong, S. S. (2020). TFEB-mediated lysosomal biogenesis and lysosomal drug sequestration confer resistance to MEK inhibition in pancreatic cancer. Cell death discovery, 612. https://doi.org/10.1038/s41420-020-0246-7
Zhao, Ben, et al. "TFEB-mediated lysosomal biogenesis and lysosomal drug sequestration confer resistance to MEK inhibition in pancreatic cancer." Cell death discovery vol. 6 (2020): 12. doi: https://doi.org/10.1038/s41420-020-0246-7
Zhao B, Dierichs L, Gu JN, Trajkovic-Arsic M, Axel Hilger R, Savvatakis K, Vega-Rubin-de-Celis S, Liffers ST, Peña-Llopis S, Behrens D, Hahn S, Siveke JT, Lueong SS. TFEB-mediated lysosomal biogenesis and lysosomal drug sequestration confer resistance to MEK inhibition in pancreatic cancer. Cell Death Discov. 2020 Mar 11;6:12. doi: 10.1038/s41420-020-0246-7. eCollection 2020. PMID: 32194992; PMCID: PMC7066197.
Copy Download .nbib Format: NLM
Share it on

Cell Death Discov. 2020 Mar 11;6:12. doi: 10.1038/s41420-020-0246-7. eCollection 2020.

TFEB-mediated lysosomal biogenesis and lysosomal drug sequestration confer resistance to MEK inhibition in pancreatic cancer.

Cell death discovery

Ben Zhao, Laura Dierichs, Jiang-Ning Gu, Marija Trajkovic-Arsic, Ralf Axel Hilger, Konstantinos Savvatakis, Silvia Vega-Rubin-de-Celis, Sven-Thorsten Liffers, Samuel Peña-Llopis, Diana Behrens, Stephan Hahn, Jens T Siveke, Smiths S Lueong

Affiliations

  1. Division of Solid Tumor Translational Oncology, German Cancer Consortium (DKTK, partner site Essen) and German Cancer Research Center, DKFZ, Heidelberg, Germany, Division of Solid Tumor Translational Oncology, German Cancer Consortium (DKTK, partner site Essen) and German Cancer Research Center, DKFZ, Heidelberg, Germany, Essen, Germany.
  2. Institute for Developmental Cancer Therapeutics, West German Cancer Center, University Hospital Essen, Essen, Germany, Heidelberg, Germany.
  3. 3Department of Hepatobiliary Surgery, the First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning Province China.
  4. 4Dept Med Oncol, West German Cancer Center, University Hospital Essen, Essen, Germany.
  5. 5Institute for Cell Biology, University Hospital Essen, Essen, Germany.
  6. 6Translational Genomics in Solid Tumors, West German Cancer Center, University Hospital Essen, Essen, Germany.
  7. EPO - Experimental Pharmacology and Oncology GmbH Berlin-Buch, Berlin, Germany.
  8. 8Department of Molecular GI-Oncology, Rurh University Bochum, Bochum, Germany.

PMID: 32194992 PMCID: PMC7066197 DOI: 10.1038/s41420-020-0246-7

Abstract

Oncogenic

© The Author(s) 2020.

Keywords: Targeted therapies

Conflict of interest statement

Conflict of interestThe authors declare that they have no conflict of interest.

References

  1. Mol Cancer. 2017 Nov 6;16(1):168 - PubMed
  2. Proc Natl Acad Sci U S A. 2018 Oct 9;115(41):E9590-E9599 - PubMed
  3. Clin Lymphoma Myeloma Leuk. 2019 Jul;19(7):431-440.e13 - PubMed
  4. BMC Cancer. 2016 Sep 29;16(1):762 - PubMed
  5. Br J Cancer. 2014 Aug 26;111(5):817-22 - PubMed
  6. Nat Med. 2019 May;25(5):861 - PubMed
  7. CA Cancer J Clin. 2016 Jan-Feb;66(1):7-30 - PubMed
  8. Eur J Cancer. 2014 Aug;50(12):2072-81 - PubMed
  9. Cancer Cell. 2017 Aug 14;32(2):185-203.e13 - PubMed
  10. J Kidney Cancer VHL. 2015 Jan 21;2(4):195-203 - PubMed
  11. J Biomol Struct Dyn. 2017 Feb;35(2):427-434 - PubMed
  12. Arch Pharm (Weinheim). 2016 Aug;349(8):573-93 - PubMed
  13. Cell Death Dis. 2018 Dec 13;9(12):1191 - PubMed
  14. Clin Cancer Res. 2011 Dec 1;17(23):7337-46 - PubMed
  15. J Exp Clin Cancer Res. 2017 Sep 7;36(1):122 - PubMed
  16. Drug Metab Dispos. 2013 Apr;41(4):897-905 - PubMed
  17. BMC Med Genomics. 2017 Mar 28;10(1):19 - PubMed
  18. Toxicol In Vitro. 2011 Apr;25(3):715-23 - PubMed
  19. Cancer Cell. 2013 Mar 18;23(3):406-20 - PubMed
  20. Nat Rev Cancer. 2015 Oct;15(10):577-92 - PubMed
  21. Mol Cancer Ther. 2019 Jul;18(7):1323-1334 - PubMed
  22. Oncogene. 2007 May 14;26(22):3291-310 - PubMed
  23. PLoS One. 2018 Jan 25;13(1):e0192059 - PubMed
  24. Oncotarget. 2015 Jan 20;6(2):1143-56 - PubMed
  25. EMBO J. 2011 Jul 29;30(16):3242-58 - PubMed
  26. Physiol Rev. 2016 Jul;96(3):805-29 - PubMed
  27. Cancer Discov. 2018 Oct;8(10):1237-1249 - PubMed
  28. Oncotarget. 2017 Jul 11;8(28):45117-45132 - PubMed
  29. Nat Genet. 2007 Mar;39(3):347-51 - PubMed
  30. Expert Opin Drug Discov. 2016 Dec;11(12):1213-1222 - PubMed
  31. Clin Cancer Res. 2018 Mar 15;24(6):1344-1354 - PubMed
  32. Cell Rep. 2014 Apr 10;7(1):86-93 - PubMed
  33. Pathol Oncol Res. 2019 Apr;25(2):769-775 - PubMed
  34. Sci Rep. 2017 Dec 6;7(1):17038 - PubMed
  35. Nat Med. 2011 Apr;17(4):500-3 - PubMed
  36. Clin Lymphoma Myeloma Leuk. 2019 Mar;19(3):142-148.e1 - PubMed
  37. Cancers (Basel). 2018 Dec 10;10(12): - PubMed
  38. Cells. 2018 Dec 08;7(12): - PubMed
  39. PLoS One. 2017 Mar 16;12(3):e0173771 - PubMed
  40. Nat Chem. 2014 Jul;6(7):614-22 - PubMed
  41. Drug Resist Updat. 2016 Jan;24:23-33 - PubMed
  42. Mol Cancer Res. 2012 Dec;10(12):1607-19 - PubMed
  43. Nat Med. 2015 Oct;21(10):1163-71 - PubMed

Publication Types